|
34 Beiträge ausgeblendet. |
|
Update Phase 2 Cabiralizumab
investor.fiveprime.com/news-releases/...s-update-phase-2-trial
Zahlen für 2019
"Five Prime expects full-year 2020 net cash used in operating activities to be between $77 and $82 million and estimates ending 2020 with cash, cash equivalents and marketable securities between $77 and $82 million"
investor.fiveprime.com/news-releases/...uarter-and-full-year-1
Deal mit Seattle Genetics
www.fiercebiotech.com/biotech/...ne-seattle-genetics-adc-deal
So schnell kann es gehen, jetzt zeigt sich deutlich wie übertrieben die Panikverkäufe Mitte März waren. Im Nachhinein gesehen waren das Top Einstiegskurse bei viele Aktien.
Zahlen für Q1/20
investor.fiveprime.com/news-releases/...t-quarter-2020-results
Zahlen für Q3/20
Clinical Pipeline:
Bemarituzumab (anti-FGFR2b) is a first-in-class isoform-selective antibody with enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) being studied in the FIGHT trial as a targeted therapy for front-line FGFR2b+/HER2- gastric and gastroesophageal junction (GEJ) cancer.
investor.fiveprime.com/news-releases/...-quarter-2020-results
142 Mio. $ Offering
Das ist ein 1A Offering, gutes Pricing und sogar noch upsized.
"Five Prime plans to use the net proceeds of the offering, together with other available funds, to fund ongoing clinical development of bemarituzumab and FPT155, to advance FPA157 through preclinical and into clinical development, to advance its late-stage research programs and for working capital and general corporate purposes."
investor.fiveprime.com/news-releases/...lic-offering-common-0
Amgen übernimmt FPRX in einem 1,9 Mrd. $ Deal
www.fiercebiotech.com/biotech/...herapeutics-a-1-9b-cash-deal
|
Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
59 | Fiveprime - geht da noch was? | Balu4u | Vassago | 24.04.21 23:29 |